- Cipher Pharmaceuticals secured a pCPA Letter of Intent (LOI) for Epuris (isotretinoin), marking a key step toward expanded public reimbursement in Canada.
- Epuris is approved for treating severe nodular, inflammatory, conglobate, and recalcitrant acne in patients aged 12 years and older.
- The LOI enables Cipher to negotiate Product Listing Agreements (PLAs) with provincial, territorial, and federal drug plans to expand patient access.
- The company said the milestone positions Epuris for broader public coverage, helping remove regional access barriers and supporting future growth.
Takeaways:
Cipher’s pCPA LOI for Epuris is a market inflection point that should expand revenue and prescription volume by shifting isotretinoin from patchy, private-pay coverage to broadly accessible public reimbursement across Canada. Once provinces and territories finalize Product Listing Agreements, Epuris will be more consistently funded and easier for dermatologists to prescribe, increasing patient access in lower-income groups and regions that previously lacked coverage
Source: CA Newswire
